Biorobotic Heart Imitates the Real Thing and Could Further Research

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 11, 2024.

By Dennis Thompson HealthDay Reporter

THURSDAY, Jan. 11, 2024 -- A biorobotic heart that combines a biological pig heart with a silicone robotic pump is providing researchers with a new tool to understand and potentially treat heart disease.

Scientists built the heart by replacing the heart muscle in the left chamber with a soft silicone robotic pump system powered by air.

When inflated, the pump twists and squeezes the heart like real heart muscle, simulating a natural heartbeat.

Using the bionic organ, researchers tested surgical methods to treat a leaky heart valve, which can trigger heart failure.

“It was really interesting for the surgeons to see every step,” said senior researcher Ellen Roche, a biomedical engineer with the Massachusetts Institute of Technology (MIT), in Boston. “When you’re working with patients, you can’t visualize the process because there’s blood in the heart.”

New treatments for heart problems must undergo rigorous testing in heart simulators and animal subjects before they are used in humans, the researchers noted in background notes.

Unfortunately, existing heart simulators have a short shelf life of two to four hours, and they don’t completely capture the complex workings of a heart. At the same time, animal studies are pricey and don’t always translate to humans.

The biorobotic heart is meant to bridge these gaps by providing a less expensive method with a shelf life of months instead of hours, researchers said.

“The simulator has a huge benefit as a research tool for those who study different heart valve conditions and interventions,” Roche noted.

“It can serve as a surgical training platform for clinicians, medical students, and trainees, allow device engineers to study their new designs, and even help patients better understand their own disease and potential treatments,” she added.

For this study, researchers focused on a disorder called mitral valve regurgitation, in which the valve between the two left heart chambers doesn’t close properly.

This causes a leaky heart valve through which blood can flow backward, leading to shortness of breath, swelling of the limbs and potentially heart failure. The condition affects more than 24 million people around the world, the researchers said.

Surgeries to fix this problem are highly complex, requiring precise techniques. So researchers used the biorobotic heart -- fitted with a damaged mitral valve -- to test three different approaches.

Heart surgeons corrected the damaged valve by anchoring the valve with artificial chords, replacing the valve with a prosthetic and implanting a device to help the valve close.

All three procedures were successful, restoring blood pressure, blood flow and heart function, researchers report.

The report was published Jan. 10 in the journal Cell Press.

The biorobotic heart also allowed the team to collect real-time data during surgery. Because the artificial blood is clear, surgeons can directly see what is happening while they work.

Given this success, Roche’s team aims to improve the biorobotic heart by making it quicker to build one and designing versions with an even longer shelf life.

They’re also exploring 3D printing technology that might allow them to recreate a synthetic human heart.

“Our biorobotic heart may help improve the device design cycle, allow rapid iterations, get things approved by regulatory bodies and launch them into the market quickly,” Roche said ina journal news release. “Expediting and improving these processes will ultimately benefit patients.”

Sources

  • Cell Press, news release, Jan. 10, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-01-12 04:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords